Background
==========

Breast cancer is the most common cancer worldwide and is the leading cause of cancer death among women.[@b1-ott-9-7039] Luminal subtype breast cancer, expressing estrogen receptor alpha (ERα) and/or progesterone receptor (PR), represents a predominant part of breast cancers.[@b2-ott-9-7039] Despite conferring a more favorable prognosis, treatment of luminal subtype breast cancer is still in controversy due to the heterogeneity of the disease and the resistance to endocrine therapy. Similar therapeutic strategies could evoke diverse responses within luminal subtype patients.[@b3-ott-9-7039],[@b4-ott-9-7039] Therefore, it is urgent to develop novel biomarkers to improve risk stratification and optimize therapy choice.

Long non-coding RNAs (lncRNAs) are a class of non-coding RNA molecules the transcripts of which are longer than 200 nt.[@b5-ott-9-7039] Although they are not protein-encoding, lncRNAs play crucial regulatory roles in a diverse range of cellular processes and biological pathways, including cancer initiation, progression and metastasis.[@b6-ott-9-7039],[@b7-ott-9-7039] Displaying tissue and cell specific expression, lncRNAs have great potential as biomarkers.[@b8-ott-9-7039]

Shen et al[@b9-ott-9-7039] have recently reported novel lncRNAs in triple-negative breast cancer. LncRNA expression profile of HER-2-enriched subtype breast cancer has also been analyzed in our previous study.[@b10-ott-9-7039] However, there is little information on the aberrant expressed lncRNAs in luminal subtype breast cancer. In this study, we aimed to uncover the dysregulated lncRNAs in luminal subtype breast cancer, which might offer potential biomarkers for prognosis evaluation and gene therapy.

Materials and methods
=====================

Sample collection and RNA extraction
------------------------------------

Three pairs of primary breast cancer tissues and adjacent non-cancerous tissues were collected in the Department of Surgical Oncology at the First Affiliated Hospital of Wenzhou Medical University. Tissue samples were snap-frozen in liquid nitrogen immediately after dissection and then stored at −80°C before RNA extraction. ERα and PR status of the samples was confirmed positive by postoperative immunohistochemistry. Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. This study was approved by the ethics committee of the First Affiliated Hospital of Wenzhou Medical University. Informed consent was obtained from all individual participants included in the study.

RNA sequencing and identification of differentially expressed lncRNAs
---------------------------------------------------------------------

The RNA with integrity number \>7.0 was optimum for cDNA library construction. The cDNA libraries were then processed for the Proton Sequencing process according to the commercial protocols. Next, Ion Proton (Life Technologies) was used to perform single-end and polyA-selection sequencing of the three pairs of samples. The MapSplice program (v2.1.6) was used to align clean reads to the human genome (version: GRCH37). We quantified the lncRNA expression as Reads Per Kilobase per Million mapped reads (RPKM) and lncRNAs with sum read counts \<10 across all samples were abandoned. EBseq algorithm was used to identify differentially expressed lncRNAs between cancer tissues and adjacent non-cancerous tissues. Differences in RNA expression were regarded as significant if values of the false discovery rate were \<0.05 and the fold change was \>2. All differentially expressed lncRNAs are listed in [Table S1](https://www.dropbox.com/sh/auoxkq4dgfjnnr0/AADX_dB8PnsLVkp3_WbSuSc2a?dl=0).

The Cancer Genome Atlas (TCGA) data set
---------------------------------------

The RPKM expression value of lncRNAs in TCGA database was downloaded through The Atlas of Non-coding RNAs in Cancer (TANRIC), which contained 837 breast cancer tissues and 105 non-tumorous tissues.[@b11-ott-9-7039] Corresponding clinical parameters and follow-up information about these 837 patients were also downloaded from TCGA database.[@b12-ott-9-7039] According to ERα and PR status, we screened out 626 samples as luminal subtype breast cancer. Clinical characteristics of the 626 luminal subtype patients as well as lncRNAs expression values are listed in [Table S2](https://www.dropbox.com/sh/auoxkq4dgfjnnr0/AADX_dB8PnsLVkp3_WbSuSc2a?dl=0).

Statistical analysis
--------------------

Mann--Whitney *U*-test was used to analyze the expression difference in lncRNAs between luminal subtype breast cancer tissues and adjacent non-cancerous tissues in TCGA cohort. Patients were divided into low or high lncRNA expression groups according to the median value. Kaplan--Meier and Cox regression analyses were utilized to assess the association between the lncRNA and overall survival of patients. A *P*-value \<0.05 was considered statistically significant. All statistical analyses were performed using SPSS Version 22.0 (Chicago, IL, USA).

Results
=======

Differentially expressed lncRNAs in luminal subtype breast cancer
-----------------------------------------------------------------

Analysis of global transcriptome expression detected 11,727 lncRNAs ([Figure S1](https://www.dropbox.com/sh/auoxkq4dgfjnnr0/AADX_dB8PnsLVkp3_WbSuSc2a?dl=0)). Volcano plot filtering found 796 lncRNAs that were significantly changed in luminal subtype breast cancer tissues compared with their adjacent non-cancerous tissues ([Figure 1A](#f1-ott-9-7039){ref-type="fig"}). Among them, 436 lncRNAs were upregulated while 360 were downregulated. The hierarchical clustering analysis showed that with the expression of these genes, the samples could be clearly classified into two groups ([Figure 1B](#f1-ott-9-7039){ref-type="fig"}). The top 20 differentially expressed lncRNAs are listed in [Table 1](#t1-ott-9-7039){ref-type="table"}. The results showed that *FAM83H antisense RNA 1* (*FAM83H-AS1*) was the most upregulated lncRNA, whereas *GSN antisense RNA 1* (*GSN-AS1*) was the most downregulated lncRNA.

TCGA cohort validation
----------------------

Mining published transcriptome sequencing data was of low cost and feasible for exploring gene expression. To validate the fidelity of our RNA sequencing data, we selected the most differentially expressed lncRNAs and detected these lncRNAs expression in TCGA cohort containing 626 luminal subtype breast cancer samples and 105 non-tumorous samples. We found that six lncRNAs were annotated in the TCGA and the results showed that *FAM83H-AS1*, *ST8SIA6 antisense RNA 1* (*ST8SIA6-AS1*) and *HOX transcript anti-sense RNA* (*HOTAIR*) were upregulated significantly in cancer tissues while *TRHDE antisense RNA 1* (*TRHDE-AS1*), *ALDH1L1 antisense RNA 2* (*ALDH1L1-AS2*) and *PGM5 antisense RNA 1* (*PGM5-AS1*) were downregulated significantly (*P*\<0.001, [Figure 2](#f2-ott-9-7039){ref-type="fig"}). The consistent variation tendency of each lncRNA showed the robustness of our RNA sequencing.

Identification of novel prognostic marker
-----------------------------------------

To determine whether lncRNAs could serve as prognostic markers in luminal subtype breast cancer, we analyzed the association between lncRNAs and prognosis in TCGA cohort. We found that high expression level of *FAM83H-AS1* was correlated with unfavorable survival. As shown in [Figure 3A](#f3-ott-9-7039){ref-type="fig"}, the difference between the survival curves of the two groups was statistically significant (*P*=0.004). The cumulative 10-year overall survival rates were 66.9% and 33.48% in the low expression group and the high expression group, respectively (*P*=0.012). With respect to the prognostic value of *FAM83H-AS1*, Cox regression analysis was conducted to adjust for clinical features. It indicated that age (hazards ratio \[HR\] =1.872, 95% CI =1.028--3.409, *P*=0.040), high *FAM83H-AS1* expression (HR =2.008, 95% CI =1.230--3.544, *P*=0.006) and lymph node metastasis (HR =1.987, 95% CI =1.145--3.449, *P*=0.015) were distinctively linked with the prognosis of luminal subtype breast cancer in univariate Cox proportional hazards regression analysis ([Table 2](#t2-ott-9-7039){ref-type="table"}). However, high *FAM83H-AS1* expression was the only independent prognostic factor after multivariate Cox proportional hazards regression analysis (HR =2.440, 95% CI =1.238--4.807, *P*=0.010). Furthermore, we found that *FAM83H-AS1* was also a prognostic marker for all breast cancer types (*P*=0.028, [Figure 3B](#f3-ott-9-7039){ref-type="fig"}). Taken together, these results indicated that *FAM83H-AS1* was an independent prognostic indicator and might act as an onco-lncRNA for breast cancer. However, other differential expressed lncRNAs failed to distinguish high-risked luminal subtype breast cancer patients ([Figure S2](https://www.dropbox.com/sh/auoxkq4dgfjnnr0/AADX_dB8PnsLVkp3_WbSuSc2a?dl=0)).

Discussion
==========

Luminal subtype breast cancer, which accounts for two-thirds of breast cancer, maintains a more differentiated state and confers a more favorable outcome than other subtypes.[@b4-ott-9-7039],[@b13-ott-9-7039] The application of adjuvant endocrine therapy has contributed to a remarkable decrease in mortality during recent decades.[@b14-ott-9-7039] However, breast cancer is highly heterogeneous and it is urgent to distinguish high-risked patients. Cheang et al reported that luminal subtype patients with high expression of HER-2 proteins and the Ki67 index had worse recurrence-free and disease-specific survival.[@b15-ott-9-7039] It has been declared that among luminal subtype patients who received tamoxifen as their sole adjuvant systemic therapy, the 10-year breast cancer specific survival was 79% for luminal A subtypes and 57% for luminal-HER2 subtypes.[@b15-ott-9-7039] Therefore, highly sensitive and specific biomarkers would be of great value in the individualized treatment for luminal subtype patients.

Deregulation of lncRNAs has also been shown to contribute to the initiation and progression of several human cancers including breast cancer.[@b16-ott-9-7039],[@b17-ott-9-7039] A previous study showed that *HOTAIR* could promote cancer metastasis by reprogramming chromatin state and was a powerful predictor of eventual metastasis and death.[@b18-ott-9-7039] In contrast, *NF-kappaB interacting long non-coding RNA* (*NKILA*) suppressed breast cancer metastasis by negatively regulating the NF-kB pathway and was associated with poor outcome.[@b19-ott-9-7039] Besides, *FGF14 antisense RNA 2* (*FGF14-AS2*) has also been proven to be correlated with progression and poorer prognosis in breast cancer in our previous study.[@b20-ott-9-7039] Hence, increasing knowledge of lncRNAs might help develop novel therapeutic targets and prognostic indicators.

To obtain comprehensive RNA expression profile data, we adopted RNA sequencing in three pairs of luminal subtype breast cancer tissues and their adjacent non-cancerous tissues. Genome-wide analysis revealed a set of lncRNAs with differential expression in cancer tissues compared with non-cancerous tissues. To the best of our knowledge, this is the only study focused on aberrant lncRNAs expression profiling in luminal subtype breast cancer. Furthermore, RNA sequencing data in TCGA database were utilized to validate the reliability of our results. Our study provided a rich resource to the research community for further identifying lncRNAs with diagnostic and therapeutic potentials and exploring biological function of lncRNAs in luminal subtype breast cancer.

Cabanski et al discovered 229 lncRNAs including *FAM83H-AS1* with differential expression across multiple cancers and hypothesized that these lncRNAs might have conserved oncogenic and tumor-suppressive functions.[@b21-ott-9-7039] Consistent with the previous study, we proved that *FAM83HAS1* was significantly upregulated in breast cancer and was related to patients' outcome in a large cohort. It was first reported that *FAM83H-AS1* was involved in luminal subtype breast cancer and as an independent prognostic indicator. Further investigation into the functions of *FAM83H-AS1* may provide additional target and strategies for treatment.

Conclusion
==========

A total of 796 significantly differentially expressed lncRNAs in luminal subtype breast cancer were identified in the present study. Moreover, *FAM83H-AS1* was demonstrated as a novel prognostic marker not only in luminal subtype breast cancer but also in all subtype breast cancers.
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![Dysregulated lncRNA expression profiles in luminal subtype breast cancer.\
**Notes:** (**A**) Volcano plot showing variation in lncRNA expression. The negative log of FDR (base 10) is plotted on the *Y*-axis, and the log of the FC (base 2) is plotted on the *X*-axis. (**B**) Heat map of differentially expressed lncRNAs in luminal subtype breast cancer tissues and adjacent non-cancerous tissues. Each column represents a single lncRNA and each row represents one tissue sample. Red indicates high relative expression, and blue indicates low relative expression.\
**Abbreviations:** FDR, false discovery rate; FC, fold change; lncRNA, long non-coding RNA.](ott-9-7039Fig1){#f1-ott-9-7039}

![LncRNA expression in TCGA cohort.\
**Notes:** The TCGA cohort contained 626 luminal subtype breast cancer tissues and 105 non-cancerous tissues. (**A**--**F**) RPKM was represented for expression level of *FAM83H-AS1*, *ST8SIA-AS1*, *HOTAIR*, *TRHDE-AS1*, *ALDH1L1-AS2* and *PGM5-AS1* in the TCGA cohort. Data were median ± interquartile ranges of RPKM value. Analysis was done using the Mann--Whitney *U*-test. \*\*\**P*\<0.001.\
**Abbreviations:** lncRNA, long non-coding RNA; TCGA, The Cancer Genome Atlas; RPKM, Reads Per Kilobase per Million mapped reads.](ott-9-7039Fig2){#f2-ott-9-7039}

![Prognostic value of *FAM83H-AS1*.\
**Notes:** (**A**) Kaplan--Meier analysis for the overall survival of 626 luminal subtype breast cancer patients with different expressions of *FAM83H-AS1* in TCGA cohort. (**B**) Kaplan--Meier analysis for the overall survival of 837 breast cancer patients with different expression of *FAM83H-AS1* in TCGA cohort.\
**Abbreviations:** *FAM83H-AS1*, *FAM83H antisense RNA 1*; TGCA, The Cancer Genome Atlas.](ott-9-7039Fig3){#f3-ott-9-7039}

###### 

Top 20 differential expressed lncRNAs

  Gene symbol      Gene ID     Type of gene   RPKM in tumor   RPKM in normal   Log2 (fold change)   FDR           Status
  ---------------- ----------- -------------- --------------- ---------------- -------------------- ------------- ---------------
  *FAM83H-AS1*     100128338   lncRNA         940.932         0.430            11.097               1.12263E-09   Upregulated
  *ST8SIA6-AS1*    100128098   lncRNA         1,792.825       0.900            10.960               1.3988E-05    Upregulated
  *HOTAIR*         100124700   lncRNA         362.095         0.194            10.870               8.42415E-12   Upregulated
  *GSN-AS1*        57000       lncRNA         0.264           490.184          −10.859              1.43495E-05   Downregulated
  *LOC100506098*   100506098   lncRNA         63.410          0.144            8.783                0.000104309   Upregulated
  *LOC101926960*   101926960   lncRNA         0.465           204.527          −8.780               1.11022E-16   Downregulated
  *LINC01405*      100131138   lncRNA         2.445           805.872          −8.365               7.76934E-13   Downregulated
  *LINC01207*      100505989   lncRNA         93.099          0.288            8.337                0.011621155   Upregulated
  *TRHDE-AS1*      283392      lncRNA         2.962           522.324          −7.462               6.85987E-11   Downregulated
  *ALDH1L1-AS2*    100862662   lncRNA         1.940           320.015          −7.366               4.76397E-13   Downregulated
  *PP14571*        100130449   lncRNA         288.086         2.502            6.847                3.99564E-07   Upregulated
  *APOC4-APOC2*    100533990   lncRNA         244.790         2.214            6.788                1.49461E-05   Upregulated
  *MESTIT1*        317751      lncRNA         0.264           27.908           −6.724               4.59753E-10   Downregulated
  *LOC101927793*   101927793   lncRNA         0.570           43.984           −6.271               9.22323E-05   Downregulated
  *LOC101929432*   101929432   lncRNA         0.310           23.763           −6.259               0.000459706   Downregulated
  *LOC101929371*   101929371   lncRNA         0.528           39.279           −6.217               0.001171094   Downregulated
  *LOC101929722*   101929722   lncRNA         1.584           116.513          −6.201               7.66724E-07   Downregulated
  *DRAIC*          145837      lncRNA         139.025         2.052            6.082                1.36844E-09   Upregulated
  *DKFZp451B082*   401282      lncRNA         0.264           17.267           −6.031               0.000251753   Downregulated
  *PGM5-AS1*       572558      lncRNA         1.144           66.580           −5.863               1.54321E-14   Downregulated

**Abbreviations:** RPKM, Reads Per Kilobases per Million reads; FDR, false discovery rate.

###### 

Cox proportional hazards regression analysis

  Variable                                                Univariate             Multivariate                                                                
  ------------------------------------------------------- ---------------------- ---------------------------------------------------- ---------------------- --------------------------------------------------
  Age (\<50 years as reference)                           1.872 (1.028--3.409)   0.040[\*](#tfn2-ott-9-7039){ref-type="table-fn"}                            
  Tumor size (T1 as reference)                            0.975 (0.546--1.743)   0.933                                                                       
  Lymph node metastasis (negative as reference)           1.987 (1.145--3.449)   0.015[\*](#tfn2-ott-9-7039){ref-type="table-fn"}                            
  Stage (stage I as reference)                            1.228 (0.620--2.430)   0.556                                                                       
  Estrogen receptor (negative as reference)               0.352 (0.048--2.578)   0.304                                                                       
  Progestrone receptor (negative as reference)            0.538 (0.276--1.048)   0.068                                                                       
  *HER-2* amplification (unamplification as reference)    1.726 (0.825--3.763)   0.144                                                                       
  *FAM83H-AS1* expression (low expression as reference)   2.008 (1.230--3.544)   0.006[\*\*](#tfn3-ott-9-7039){ref-type="table-fn"}   2.440 (1.238--4.807)   0.010[\*](#tfn2-ott-9-7039){ref-type="table-fn"}

**Note:**

*P*\<0.05,

*P*\<0.01.

**Abbreviations:** CI, confidence interval; HR, hazard ratio.
